Comparative Pharmacology
Head-to-head clinical analysis: ELLENCE versus IDAMYCIN PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELLENCE versus IDAMYCIN PFS.
ELLENCE vs IDAMYCIN PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELLENCE (epirubicin) is an anthracycline cytotoxic antibiotic. It intercalates between DNA base pairs, inhibits topoisomerase II activity, and generates free radicals, leading to DNA damage and cell death.
Idarubicin is an anthracycline antineoplastic antibiotic that intercalates with DNA and inhibits topoisomerase II, resulting in DNA strand breaks and inhibition of nucleic acid synthesis.
60-120 mg/m2 IV bolus or slow infusion on Day 1 every 21-28 days; or 20-30 mg/m2 IV daily for 3 days repeated every 28 days.
12 mg/m² intravenously over 10 to 15 minutes daily for 3 days (induction) or 12 mg/m² intravenously daily for 2 days (consolidation).
None Documented
None Documented
Terminal elimination half-life is approximately 20-40 hours (mean ~30 hours). This supports a 3-week dosing interval to allow for recovery from myelosuppression.
Terminal elimination half-life of idarubicin is 20-30 hours; idarubicinol (active metabolite) has a terminal half-life of 45-60 hours, extending myelosuppression duration.
Primarily hepatobiliary excretion: ~40-50% of dose excreted as unchanged drug and metabolites in bile and feces. Renal excretion accounts for <10% (mostly as metabolites).
Renal (approximately 5-12% as unchanged drug and metabolites), biliary/fecal (significant, with 40-50% recovered in feces over 7 days).
Category C
Category C
Anthracycline Antineoplastic
Anthracycline Antineoplastic